IL171987A0 - The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma - Google Patents

The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma

Info

Publication number
IL171987A0
IL171987A0 IL171987A IL17198705A IL171987A0 IL 171987 A0 IL171987 A0 IL 171987A0 IL 171987 A IL171987 A IL 171987A IL 17198705 A IL17198705 A IL 17198705A IL 171987 A0 IL171987 A0 IL 171987A0
Authority
IL
Israel
Prior art keywords
fumaric acid
acid derivatives
asthma
cardiac insufficiency
treating cardiac
Prior art date
Application number
IL171987A
Other versions
IL171987A (en
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/009835 external-priority patent/WO2005023241A1/en
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of IL171987A0 publication Critical patent/IL171987A0/en
Publication of IL171987A publication Critical patent/IL171987A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FIELD: medicine, pharmaceutics. ^ SUBSTANCE: what is presented is using fumaric acid derivatives specified in a group consisting of dialkylfumarates, monoalkylhydrofumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, fumaric acid monoamide salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds or their mixtures for preparing a drug for treatment or prevention of cardiac failure, particularly left-ventricular failure, myocardial infarction and angina. ^ EFFECT: dimethylfumarate has appeared to reduce considerably an area of infarction caused by ischemia followed by reperfusion. ^ 19 cl, 4 dwg, 7 ex
IL171987A 2003-09-09 2005-11-15 Use of fumaric acid derivatives for preparing a drug for treating or prevention of cardiac insufficiency, myocardial infarct and angina pectoris IL171987A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10341530 2003-09-09
DE10360869A DE10360869A1 (en) 2003-09-09 2003-12-23 Use of fumaric acid derivatives for the treatment of heart failure, hyperkeratosis and asthma
PCT/EP2004/009835 WO2005023241A1 (en) 2003-09-09 2004-09-03 The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma

Publications (2)

Publication Number Publication Date
IL171987A0 true IL171987A0 (en) 2006-04-10
IL171987A IL171987A (en) 2010-12-30

Family

ID=34258515

Family Applications (1)

Application Number Title Priority Date Filing Date
IL171987A IL171987A (en) 2003-09-09 2005-11-15 Use of fumaric acid derivatives for preparing a drug for treating or prevention of cardiac insufficiency, myocardial infarct and angina pectoris

Country Status (12)

Country Link
JP (3) JP2008529959A (en)
CN (2) CN1829505B (en)
AT (1) ATE447946T1 (en)
CY (1) CY1107849T1 (en)
DE (2) DE10360869A1 (en)
HK (1) HK1094650A1 (en)
IL (1) IL171987A (en)
NZ (1) NZ543708A (en)
PT (1) PT1663197E (en)
RS (1) RS51881B (en)
RU (2) RU2459621C2 (en)
ZA (1) ZA200601985B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602496A (en) 2008-08-19 2013-09-27 Xenoport Inc Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
EP3295936A1 (en) * 2009-01-09 2018-03-21 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
HK1252751A1 (en) * 2009-01-09 2019-05-31 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP2782561A1 (en) * 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130216615A1 (en) * 2012-02-07 2013-08-22 David Goldman Pharmaceutical Compositions Containing Dimethyl Fumarate
WO2014031897A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms having a high loading of (n,n- diethylcarbamoyl)methyl methyl|(2e)but-2-ene-1,4-dioate
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
KR101379427B1 (en) * 2013-02-13 2014-03-28 경북대학교병원 Composition for preventing or treating renal fibrosis comprising dimethylfumarate
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (en) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド Crystal form of (N, N-diethylcarbamoyl) methyl methyl (2E) but-2-ene-1,4-dioate, its synthesis and use
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
DE19721099C2 (en) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Use of fumaric acid derivatives
DE19814358C2 (en) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Use of alkyl hydrogen fumarates for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and enteritis regionalis Crohn
DE19839566C2 (en) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Use of fumaric acid derivatives in transplant medicine
DE19853487A1 (en) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
DE10101307A1 (en) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumaric acid derivatives as NF-kappaB inhibitor
EP1372634B1 (en) * 2001-01-12 2009-11-11 Biogen Idec International GmbH Use of fumaric acid amides
RU2189813C1 (en) * 2001-06-01 2002-09-27 Российский научно-исследовательский институт гематологии и трансфузиологии Antihypoxic medicinal agent
DE10217314A1 (en) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclic and oxacarboncyclic fumaric acid oligomers

Also Published As

Publication number Publication date
CN1829505A (en) 2006-09-06
JP2008529959A (en) 2008-08-07
ZA200601985B (en) 2007-05-30
RU2012115860A (en) 2013-10-27
JP2015155480A (en) 2015-08-27
CY1107849T1 (en) 2013-06-19
CN102058574B (en) 2013-02-13
DE10360869A1 (en) 2005-04-07
CN1829505B (en) 2010-11-10
RS51881B (en) 2012-02-29
RS20050948A (en) 2008-04-04
PT1663197E (en) 2007-12-26
HK1094650A1 (en) 2007-04-04
JP5784877B2 (en) 2015-09-24
NZ543708A (en) 2008-11-28
DE602004024143D1 (en) 2009-12-24
CN102058574A (en) 2011-05-18
ATE447946T1 (en) 2009-11-15
IL171987A (en) 2010-12-30
RU2007138216A (en) 2009-04-20
JP2010070563A (en) 2010-04-02
RU2459621C2 (en) 2012-08-27

Similar Documents

Publication Publication Date Title
IL171987A0 (en) The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
AU2016366220B2 (en) Compounds useful in the treatment and/or care of the skin, hair, nails, and/or mucous membranes
EA200101166A1 (en) Metalloprotease inhibitors
ME01310B (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
CA2414967A1 (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
TR200200648T2 (en) New dicarboxylic acid derivatives with pharmaceutical properties.
MY161092A (en) 3h-imidazo [4, 5 -c] pyridine- 6 - carboxamides as anti- inflammatory agents
EP1592665A4 (en) Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
RU94040170A (en) Isoquinolines
SG154333A1 (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
EA200801492A1 (en) PHARMACEUTICAL APPLICATION OF SUBSTITUTED AMIDES
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
UA105018C2 (en) Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
ITRM20020014A1 (en) DERIVATIVES OF A-PHENYLTHIOCARBOXYL AND A-PHYLYOXYCARBOXYL ACIDS USEFUL FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE ACTIVATION OF
AR036623A1 (en) REPAGLINIDA PREPARATION PROCESS
ES2163805T3 (en) DERIVATIVES OF BENZOFURAN-ACRYLIC ACIDS AND ITS USE AS MODULATORS OF RXRS OR RARS RECEIVERS.
CA2362833A1 (en) Phenylalaninol derivatives
DE60119514D1 (en) AMID DERIVATIVES OF 2-AMINO-3-HYDROXY-4-TERT-LEUCYL-AMINO-5-PHENYL-PENTANIC ACID
GEP20053636B (en) Isoquinoline Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them
TR200101980T2 (en) Arilalkanoil derivatives, their preparation processes
TR200102009T2 (en) The use of compounds according to formula I for prophylaxis and treatment of cerebral process
TW200500342A (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl]benz-amide, its use as a medicament, and pharmaceutical preparations comprising it
AR030945A1 (en) AMIDAS OF FENILCICLOHEXANOCARBOXILICO SUBSTITUTED ACID AND USE
MX2009005676A (en) Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders.
ATE546137T1 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING WARTS

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees